| Literature DB >> 33996405 |
Yongchao Wang1,2,3, Jinjin Wang2,3, Dandan Zhu1, Yufei Wang2,3, Guangchao Qing2,3, Yuxuan Zhang2,3, Xiaoxuan Liu1, Xing-Jie Liang2,3.
Abstract
Current advances of immunotherapy have greatly changed the way of cancer treatment. At the same time, a great number of nanoparticle-based cancer immunotherapies (NBCIs) have also been explored to elicit potent immune responses against tumors. However, few NBCIs are nearly in the clinical trial which is mainly ascribed to a lack understanding of in vivo fate of nanoparticles (NPs) for cancer immunotherapy. NPs for cancer immunotherapy mainly target the immune organs or immune cells to enable efficient antitumor immune responses. The physicochemical properties of NPs including size, shape, elasticity and surface properties directly affect their interaction with immune systems as well as their in vivo fate and therapeutic effect. Hence, systematic analysis of the physicochemical properties and their effect on in vivo fate is urgently needed. In this review, we first recapitulate the fundamentals for the in vivo fate of NBCIs including physio-anatomical features of lymphatic system and strategies to modulate immune responses. Moreover, we highlight the effect of physicochemical properties on their in vivo fate including lymph nodes (LNs) drainage, cellular uptake and intracellular transfer. Challenges and opportunities for rational design of NPs for cancer immunotherapy are also discussed in detail.Entities:
Keywords: Cancer treatment; Cellular uptake; Immune responses; Intracellular transfer; In vivo fate; Lymph nodes drainage; Nanoparticle-based cancer immunotherapies; Physicochemical properties
Year: 2021 PMID: 33996405 PMCID: PMC8105773 DOI: 10.1016/j.apsb.2021.03.007
Source DB: PubMed Journal: Acta Pharm Sin B ISSN: 2211-3835 Impact factor: 11.413
Figure 1Schematic illustration of lymphatic vessels and lymph node. (A) Initial lymphatic vessels paralleled with blood capillary stretched into the interstitium. Initial lymphatic vessels with blind-ended structures and discontinuous basement membrane, while the blood capillary with tight junction of endothelial cells. (B) The structure of lymph node which can be divided into cortex, paracortex and medulla zone. Reproduced with the permission from Ref. 57. Copyright © 2015 Springer Nature.
Figure 2Nanoparticle based immunotherapy target lymph node and DC cells. Adjuvant CpG was engineered into NPs for enhanced lymph node accumulation. (A) CpG was conjugated to different type of lipid to form NPs. (B) Fluorescent image of lymph node removed from mice injected with different formulations. (C) Quantification of the fluorescent image of lymph node. (D) CpG retention in the lymph node of different formulation 7 days after injection. Reproduced with the permission from Ref. 60. Copyright © 2014 Springer Nature.
Figure 3Nanoparticle based immunotherapy target T cells in circulation. (A) Schematic illustration of the NPs structure targeting and modifying the T cells in circulation. (B) Components and preparation of the polymer-based NPs for T cells targeting. Reproduced with the permission from Ref. 76. Copyright © 2017 Springer Nature.
Strategies for nanoparticle-based cancer immunotherapies (NCBIs) to modulate immune responses.
| Target cell | NPs platform | Immunotherapeutic agent | Function | Ref. |
|---|---|---|---|---|
| DCs | Ionizable lipid-like materials | mRNA or antigens | Efficient mRNA delivery and STING activation | |
| pH-sensitive polymers | Antigens | Efficient antigen cytosolic delivery and STING activation | ||
| Albumin-binding lipids | CpG or peptide | Enhanced lymph node delivery and T Cell activation | ||
| Polymers | Antigens and adjuvants | Robust humoral and cellular immunity | ||
| Mesoporous silica rod absorbing PEI | CpG, antigens and GM-CSF | Promote dendritic cell activation and antigen specific T cell responses | ||
| T cells | Nanoscale polymeric gels | TGF- | Facilitate the CD8+ T-cell infiltration into tumors | |
| PLGA/PEG-based NPs | TGF | Improve the viability of endogenous T cells and its antitumor efficiency | ||
| liposomes and liposome-like synthetic NPs | Adjuvant drugs | Boosted the viability and proliferation of T cells | ||
| Reactive oxygen species–responsive scaffold | Gemcitabine and checkpoint inhibitor | Improve the activity of CD8+ T cells for efficient cancer eradication | ||
| Gold NPs | Checkpoint inhibitors | Enhanced antitumor effect and rapid prediction of therapeutic response | ||
| Other immune cells | Bisphosphonate-glucomannan conjugate | Bisphosphonate and glucomannan | Efficiently reduced the percentage of TAMs | |
| Ferumoxytol | Ferumoxytol | Inhibit tumor growth by converting M2-like TAM into M1-like TAM | ||
| Graphene oxide-based nanoscale clusters | Antibodies | Significantly stimulate NK cells activity | ||
| Phosphonate capped dendrimers | Phosphonate capped dendrimers | Efficient proliferation of human NK cells | ||
| Lipid NPs | Lauroyl-modified gemcitabine | Reduce the percentage of MDSCs in the spleen and tumor | ||
| Heparin-tocopherol succinate nanoparticle | Heparin-tocopherol Succinate nanoparticle | Inhibit the recruitment of MDSCs and expression of MMP-9 in MDSCs |
DCs, dendritic cells; GM-CSF, granulocyte–macrophage colony-stimulating factor; MDSCs, myeloid-derived suppressor cells; MMP-9, matrix metalloprotein 9; mRNA, messenger RNA; NK cells, natural killer cells; NPs, nanoparticles; PEI, polyethylenimine; TAM, tumor-associated macrophages; TGF-β, transforming growth factor-β; TGFβR1, transforming growth factor beta-receptor 1; TLR7/TLR8, toll-like receptor 7/8.
Figure 4Small NPs are more readily accumulate in the lymph node. (A) Fluorescence microlymphangiography of lymphatic vessels after injection of 100 nm and 25 nm NPs. (B) Location and retention of NPs in the lymph node. (C) CD11c + cells with 100 nm and 25 nm NPs analyzed by flow cytometer. (D) Quantification of CD11c + cells with 100 nm and 25 nm NPs. Reproduced with the permission from Ref. 50. Copyright © 2007 Springer Nature.
Figure 5Schematic illustration of small and large NPs transferred in the interstitial matrix. Small NPs can transfer through the interstitial freely, while the large NPs is entrapped within the matrix. Reproduced with the permission from Ref. 55. Copyright © 2015 Elsevier.
Figure 6NPs with different charge state for lymph node targeting. (A) Schematic illustration of NPs with different charge absorbing antigens released from radiotherapy drained to lymph node. (B) Charge state of different NPs absorbing antigens or not. (C) Fluorescence image of lymph node injected with different formulations. Reproduced with the permission from Ref. 105. Copyright © 2017 Springer Nature.
Figure 7Effect of particle elasticity on cellular uptake and lymph node accumulation. (A) Particles with pliability and lateral mobility deform on the cell surface for enhanced cellular uptake. (B) Rigid particles did not deform on the cell surface with reduced cellular uptake. (C) Comparison of antigen presentation of nanoparticle with different elasticity. (D) Fluorescence image of lymph node accumulation after injected with different formulations. Reproduced with the permission from Ref. 111. Copyright © 2018 Springer Nature.
Figure 8Effect of shape on cellular uptake by RAW264.7 macrophages. (A) TEM images of spherical, cubic and rod Au NPs. (B) Characterization of ζ potential of Au-NPs after modification. (C) Cellular uptake of Au-NPs with different shape observed by CLSM. (D) Antibody production treated with different formulations. Reproduced with the permission from Ref. 128. Copyright © 2013 American Chemical Society.
Figure 9NPs with pH responsivity for intracellular delivery of antigens. (A) Schematic illustration of polymer based nanovaccine for efficient antigen cytosolic delivery and robust tumor inhibition. (B) Chemical structure of polymers with linear or cyclic tertiary amines in the side chains. (C) Antigen presentation with free OVA or OVA encapsulated in the pH responsive polymers. (D) Tumor growth inhibition rate of mice bearing B16-OVA after immunized by different formulations. Reproduced with the permission from Ref. 59. Copyright © 2017 Springer Nature.